Acute Coronary Syndromes
"Irrational" choices stall adoption of new antiplatelets
7 COMMENT S - Feb 6, 2012 09:15 EST
Dr David Cohen points out some of physicians' potential "psychological" barriers to more rapid adoption of new antiplatelet agents, even though they may be the best choice for their patients.

Washington, DC - Adoption of new antiplatelet agents such as ticagrelor (Brilinta/Brilique, AstraZeneca) and prasugrel (Effient, Lilly/Daiichi-Sanyo) for ACS patients has been slow so far because many doctors have not properly understood the bleeding-thrombosis trade-off, Dr David Cohen (St Luke's Mid America Heart Institute, Kansas City, MO) explained here at CRT 2012, the Cardiovascular Research Technologies conference [1].

During a session on antiplatelet drugs for ACS, Dr Michael Gibson (Beth Israel Deaconess, Boston, MA) mentioned that in the first five months since the FDA approved ticagrelor, only 1700 prescriptions for the drug have been written. "That's pretty slow," Cohen remarked, especially compared with the relatively rapid uptake of clopidogrel in the late 1990s as a safer alternative to ticlopidine.
Read full article »

Features
The doctor will see you now (from the other side of the world)
Updated with video
Feb 10, 2012 12:30 EST

Thrombosis
US judge upholds FDA approval of generic enoxaparin
Feb 9, 2012 16:30 EST

Prevention
Like father, like son: Y-chromosome variant may explain CAD
Feb 8, 2012 18:30 EST

Acute Coronary Syndromes
SWITCH III: Bivalirudin is as safe as heparin after fondaparinux in PCI patients
Feb 7, 2012 12:30 EST

Acute Coronary Syndromes
TRA 2°P: Vorapaxar meets end point but ups bleeding
Feb 7, 2012 12:20 EST

Acute Coronary Syndromes
CTO, even in non-infarct-related artery, bodes ill in NSTEMI patients
Feb 7, 2012 09:45 EST

Editorial programs
Debate and dialogue between top cardiovascular specialists, produced by
theheart.org's editorial team
View all »
Life and times of leading cardiologists with Rob Califf. Guest: Martin Leon
Life and times of leading cardiologists with Rob Califf. Guest: Martin Leon
1 COMMENT - Feb 7, 2012 09:00 EST
Antithrombotic therapies in ACS: An update from Europe
Antithrombotic therapies in ACS: An update from Europe
Jan 30, 2012 10:30 EST
All about dronedarone, from ATHENA to PALLAS
All about dronedarone, from ATHENA to PALLAS
1 COMMENT - Jan 6, 2012 07:30 EST
The Heart of a Woman
The Heart of a Woman
The Heart of a Woman
2 COMMENTS - Apr 27, 2009 13:25 EDT
Resource Center (view all)